Johnson & Johnson (NYSE:JNJ) Holdings Reduced by Cynosure Advisors LLC

Cynosure Advisors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 18.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,743 shares of the company’s stock after selling 2,034 shares during the period. Cynosure Advisors LLC’s holdings in Johnson & Johnson were worth $1,120,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Claraphi Advisory Network LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $1,481,000. Penobscot Investment Management Company Inc. increased its stake in Johnson & Johnson by 0.8% in the fourth quarter. Penobscot Investment Management Company Inc. now owns 75,273 shares of the company’s stock valued at $10,517,000 after purchasing an additional 583 shares in the last quarter. Aveo Capital Partners LLC increased its stake in Johnson & Johnson by 10.9% in the fourth quarter. Aveo Capital Partners LLC now owns 5,689 shares of the company’s stock valued at $795,000 after purchasing an additional 561 shares in the last quarter. MUFG Securities EMEA plc increased its stake in Johnson & Johnson by 42.5% in the fourth quarter. MUFG Securities EMEA plc now owns 620,000 shares of the company’s stock valued at $86,626,000 after purchasing an additional 185,000 shares in the last quarter. Finally, Calton & Associates Inc. bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $1,978,000. Institutional investors and hedge funds own 66.67% of the company’s stock.

JNJ has been the subject of several recent analyst reports. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a research note on Friday, September 14th. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, July 13th. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Finally, Sanford C. Bernstein initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 target price for the company. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $143.91.

In related news, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by company insiders.

Shares of JNJ stock opened at $139.39 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.32. The firm has a market cap of $370.70 billion, a PE ratio of 19.09, a P/E/G ratio of 2.19 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The company had revenue of $20.83 billion during the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter in the prior year, the firm earned $1.83 earnings per share. The firm’s revenue was up 10.6% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 8.14 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th were given a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date was Monday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Marijuana Stocks Future Looks Bright

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply